Accendra Health stock: Earnings are due October 29 for Accendra Health stock

Published on 10/22/2026 at 22:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue outlook is USD 2.45 billion to USD 2.55 billion. Accendra Health stock costs EUR 0.19 on October 22, 2026, down 3.47 percent on the day on the NYSE.

Reporting date and outlook

Accendra Health's next earnings release is scheduled for October 29, 2026.
Second-quarter 2026 adjusted EBITDA exceeded USD 60 million.
Accendra Health stock costs EUR 0.19 at Lang & Schwarz on October 22, 2026 at 10:13 p.m. CEST, down 3.47 percent on the NYSE.
Full-year 2026 revenue outlook is USD 2.45 billion to USD 2.55 billion.

ACH, US6907321029, Illustration mit AI erstellt.

Accendra Health (ISIN US6907321029) has its next earnings release scheduled for October 29, 2026, according to Zacks. The date gives investors a near-term checkpoint after a difficult second quarter. At Lang & Schwarz, the stock was trading at EUR 0.19 on October 22, 2026 at 10:13 p.m. CEST, while the NYSE quote was down 3.47 percent on the day.

Revenue outlook sets the test

Accendra Health's second-quarter 2026 revenue was USD 613.20 million, while revenue excluding the exited commercial payer grew 2.00 percent year over year. The Q2 2026 earnings call also put adjusted EBITDA above USD 60 million, according to Fortune.

The company set its full-year 2026 revenue outlook at USD 2.45 billion to USD 2.55 billion and adjusted EBITDA at USD 300.00 million to USD 320.00 million. The range places execution, collections and cost control at the center of the October 29 update.

NYSE price remains near its low

The NYSE quote was USD 0.21 at 3:59 p.m. ET on October 22, 2026, against a previous close of USD 0.22. The 52-week range was USD 0.20 to USD 5.60, putting the quote USD 0.01 above the low and USD 5.39 below the high.

Accendra Health's market capitalization was USD 16.2 million on October 22, 2026. The company operates in healthcare distribution and home-based care, with products and services covering diabetes, respiratory therapy, sleep apnea, ostomy and urology.

Debt remains a central measure

Total debt was USD 1.72 billion in the second quarter of 2026, while net debt was more than USD 55.00 million lower than at the end of March, according to Fortune. Management said full-year 2026 fully levered free cash flow was expected to be break-even to slightly positive.

Comparison with peers

Cardinal Health (NYSE, USD): down 0.71 percent, price-to-earnings ratio 35.36, market capitalization USD 59.2 billion.

McKesson (NYSE, USD): down 0.31 percent, price-to-earnings ratio 27.09, market capitalization USD 118.0 billion.

The next reporting marker

The October 29, 2026 earnings release will put the revenue range, adjusted EBITDA outlook and cash-flow trajectory back in front of the market. The scheduled date is listed by Yahoo Finance.

Accendra Health was trading at EUR 0.19 at Lang & Schwarz on October 22, 2026 at 10:13 p.m. CEST, with the NYSE quote down 3.47 percent on the day.

The further course of trading is shown by the continuously updated real-time quote of Accendra Health stock.